William Blair analyst Margaret Kaczor has maintained their bullish stance on RMD stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Margaret Kaczor’s rating is based on ResMed’s strong financial performance in the recent fiscal quarter, which exceeded sales and earnings expectations. The company’s exemption from the recent tariffs further strengthens its position, making it a safer investment compared to others affected by these economic changes. This positive outlook supports the view that ResMed is a compelling investment opportunity for the foreseeable future.
Additionally, ResMed’s consistent performance over recent quarters and the robust demand for its products reinforce the belief that the company is well-positioned to capitalize on trends in sleep health. The potential for margin expansion and upcoming product launches are expected to drive growth, and despite trading at a lower multiple compared to its high-growth peers, the fundamentals of this medtech company remain strong. These factors contribute to the Buy rating assigned by Margaret Kaczor.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $280.00 price target.